跳转至内容
Merck

A79809

Sigma-Aldrich

5-氨基水杨酸

95%

别名:

5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸

登录查看公司和协议定价


About This Item

线性分子式:
H2NC6H3-2-(OH)CO2H
CAS号:
分子量:
153.14
Beilstein:
2090421
EC號碼:
MDL號碼:
分類程式碼代碼:
12352106
PubChem物質ID:
NACRES:
NA.22

品質等級

化驗

95%

形狀

powder with small lumps

反應適用性

reaction type: solution phase peptide synthesis

mp

275-280 °C (dec.) (lit.)

應用

detection
peptide synthesis

SMILES 字串

Nc1ccc(O)c(c1)C(O)=O

InChI

1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

InChI 密鑰

KBOPZPXVLCULAV-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

應用

5-氨基水杨酸是适用于ELISA分析的过氧化物酶底物。这一底物产生可溶性的棕色终产物,可在450nm处通过分光光度法读取。使用3 N NaOH可终止反应并在550 nm处读取结果。

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

13 - Non Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

No data available

閃點(°C)

No data available

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

W Kruis et al.
Alimentary pharmacology & therapeutics, 37(7), 680-690 (2013-02-19)
Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse. To investigate mesalazine (Salofalk granules) in this setting. In a double-blind, placebo-controlled, multicentre, 6-week trial, patients were randomised to mesalazine 1000 mg three times daily or placebo.
Urpo Nieminen et al.
International journal of cancer, 134(1), 189-196 (2013-06-26)
Patients with long-standing inflammatory bowel disease (IBD) have an increased risk for colorectal carcinoma (CRC). Earlier studies suggest that the severity of inflammation is an independent risk factor for CRC in ulcerative colitis (UC). We investigated the role of histological
Mirjana Rajilić-Stojanović et al.
Inflammatory bowel diseases, 19(3), 481-488 (2013-02-07)
Presence of intestinal microbes is a prerequisite for the development of ulcerative colitis (UC), although deviation of the normal intestinal microbiota composition, dysbiosis, is presumably implicated in the etiology of UC. The fecal microbiota of 30 UC samples obtained from
Christian P Selinger et al.
Inflammatory bowel diseases, 19(10), 2199-2206 (2013-08-01)
Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets
B Flourié et al.
Alimentary pharmacology & therapeutics, 37(8), 767-775 (2013-03-05)
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. To compare the efficacy and safety of once- (OD) vs. twice- (BD) daily prolonged-release mesalazine (Pentasa, Ferring, Saint-Prex, Switzerland) for active mild-to-moderate UC in a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门